TY - JOUR
T1 - Testosterone replacement therapy in older male subjective memory complainers: Double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety
AU - Asih, Prita
AU - Wahjoepramono, E.J.
AU - Aniwiyanti, V.
AU - Wijaya, L.K.
AU - De Ruyck, K.
AU - Taddei, Kevin
AU - Fuller, S.J.
AU - Sohrabi, H.
AU - Dhaliwal, S.S.
AU - Verdile, Giuseppe
AU - Carruthers, M.
AU - Martins, Ralph
PY - 2015
Y1 - 2015
N2 - © 2015 Bentham Science Publishers. Testosterone replacement therapy (TRT) has been investigated in older men as a preventative treatment against Alzheimer’s disease and dementia. However, previous studies have been contradictory. We assessed TRT physiological effects in 44 older men (aged 61 ± 7.7 years) with subjective memory complaints using a double blind, randomized, crossover, placebo-controlled study. Participants were randomized into 2 groups, one group received transdermal testosterone (50 mg) daily for 24 weeks, followed by a 4 week wash-out period, then 24 weeks of placebo; the other group received the reverse treatment. Blood evaluation revealed significant increases in total testosterone, free (calculated) testosterone, dihydrotestosterone, and a decrease in luteinizing hormone levels (p
AB - © 2015 Bentham Science Publishers. Testosterone replacement therapy (TRT) has been investigated in older men as a preventative treatment against Alzheimer’s disease and dementia. However, previous studies have been contradictory. We assessed TRT physiological effects in 44 older men (aged 61 ± 7.7 years) with subjective memory complaints using a double blind, randomized, crossover, placebo-controlled study. Participants were randomized into 2 groups, one group received transdermal testosterone (50 mg) daily for 24 weeks, followed by a 4 week wash-out period, then 24 weeks of placebo; the other group received the reverse treatment. Blood evaluation revealed significant increases in total testosterone, free (calculated) testosterone, dihydrotestosterone, and a decrease in luteinizing hormone levels (p
M3 - Article
SN - 1871-5273
VL - 14
SP - 576
EP - 586
JO - CNS and Neurological Disorders - Drug Targets
JF - CNS and Neurological Disorders - Drug Targets
IS - 5
ER -